ClinicalTrials.gg
RecruitingNCT05257629ASAPUpdated Apr 29, 2025

Aggressive Smoking Cessation Trial (ASAP)

A Phase 3 interventional study of Combination Therapy Arm (Varenicline and Nicotine E-Cigarettes Plus Counseling) and Varenicline Plus Counseling in Acute Coronary Syndrome and Cardiovascular Diseases, sponsored by Sir Mortimer B. Davis - Jewish General Hospital. Recruiting at 13 sites in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-04-29.

Sponsored by Sir Mortimer B. Davis - Jewish General Hospital · Phase 3, Interventional, and Prevention

How we know

From the registry’s dates

  • Primary completion was expected by Mar 2026, 8 months ago, but the record still lists the study as recruiting.
  • Started Feb 2023; still recruiting 3 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
798
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 104 studies in Acute Coronary Syndrome with a site in Canada — 9 open to participants now, 13 under way, 4 of them phase 3. Acute Coronary Syndrome · Canada.

Planned enrollment
39th of 90
798 · median 504
Started
2023
with 4 others
Phase 3
31 of 104
3 open now
Primary completion
2026-03
later than 4 of 12 live
Registered
92nd of 104
by date

Among the 104 studies in Acute Coronary Syndrome with a site in Canada, this one is the 39th largest by planned enrollment of the 90 interventional ones that give a count, is one of 5 that started in 2023, is one of 31 in phase 3, reaches primary completion later than 4 of the 12 other live ones, and was the 92nd registered.

Acute Coronary Syndrome

1,491 studies on the registry are indexed under Acute Coronary Syndrome; 272 are open to participants now.

Browse Acute Coronary Syndrome studies →

Open to participants now

9 of the 104 studies in Acute Coronary Syndrome with a site in Canada are open now. Recruiting first, the newest first:

3 more — sign in →

All 9 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 195 Acute Coronary Syndrome studies recruiting now, 144 (74%) set no upper age limit and 19 (10%) stop at 75 or younger; 15 take children under 18; 15 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 104 studies in Acute Coronary Syndrome with a site in Canada, or all of them as a file.
02

Study summary

The ASAP Trial is a 5-year, multi-centre, randomized controlled trial that will assess the efficacy, safety, and tolerability of aggressive smoking cessation therapy among people at elevated cardiovascular risk. It will recruit 798 adult patients smoking on average at least 10 conventional (tobacco) cigarettes per day who are motivated to quit smoking and have either been diagnosed with ACS requiring hospitalization or are outpatients at elevated cardiovascular risk. Patients will be randomized (1:1) to one of two treatment arms: (1) combination therapy of varenicline and nicotine e-cigarettes plus counseling or (2) varenicline plus counseling for 12 weeks, with 52-week follow-up.

Read the detailed description

Background and Importance:

People who smoke are at an elevated risk of developing cardiovascular disease (CVD). Those who have an acute coronary syndrome (ACS), including myocardial infarction and unstable angina, and continue to smoke have a 35% increased risk of reinfarction or death compared with those who quit. Our previous smoking cessation trials have established varenicline (Champix) as the "gold standard" for patients with CVD. However, more than 50% of patients motivated to quit who receive varenicline for 12 weeks immediately post-ACS will return to smoking within 6 months. Therefore, more effective smoking cessation strategies are needed. Based on newly available data from randomized controlled trials (RCTs), including our E3 Trial, which suggest that nicotine e-cigarettes are more efficacious for smoking cessation than other nicotine replacement therapies and counseling alone, the investigators propose to combine varenicline and nicotine e-cigarettes (aggressive smoking cessation therapy). The proposed aggressive therapy is a novel approach needed now to increase abstinence in people at elevated cardiovascular risk.

Goal(s)/Research Aims:

The Aggressive Smoking Cessation Therapy Among People at Elevated Cardiovascular Risk (ASAP) Trial is a 5-year, multi-centre RCT that will assess the efficacy, safety, and tolerability of aggressive smoking cessation therapy among people at elevated cardiovascular risk. The specific aims are:

  1. To assess the efficacy of combination therapy (varenicline and nicotine e-cigarettes) versus varenicline alone for 12 weeks, in terms of biochemically-validated 7-day point prevalence and continuous smoking abstinence, and ≥50% reduction in daily cigarette consumption at 24 and 52 weeks among people at elevated cardiovascular risk.
  2. To describe the safety and tolerability of varenicline combined with nicotine e-cigarettes, in terms of serious adverse events (SAEs), adverse events (AEs), treatment discontinuation due to side effects, and therapy adherence over the 12-week treatment period.

Methods/Approaches/Expertise:

A total of 798 participants will be randomized 1:1 to: (1) varenicline and nicotine e-cigarettes (aggressive smoking cessation therapy), or (2) varenicline alone for 12 weeks, with follow-up of 52 weeks. Both arms will receive individual smoking cessation counseling. Participants randomized to aggressive therapy (varenicline and nicotine e-cigarette) will be given funds to cover the purchase of e-cigarettes and nicotine cartridges. Funds will be provided at baseline for the first 4 weeks of e-cigarette use. Participants who follow the e-cigarette purchasing instructions and provide receipts at subsequent clinic visits will be provided additional funds at week 4 (for weeks 4 to 8) and reimbursed at week 12 (for weeks 8 to 12). Participants will begin varenicline (titrated to 1.0 mg twice daily) and counseling at baseline, and e-cigarette use (if applicable) after the baseline visit. Eligible people will have or be at elevated risk of developing CVD, self-identify as regular smokers (≥10 cigarettes/day for ≥1 year), and be motivated to quit. They will complete telephone follow-ups at weeks 1, 2, 8, and 18, and clinic visits at weeks 4, 12, 24, and 52. We will collect information about self-reported smoking, treatment adherence, and adverse events. Self-reported smoking abstinence will be biochemically-validated at clinic visits using exhaled carbon monoxide (≤10 ppm). The primary endpoint will be biochemically-validated 7-day point prevalence smoking abstinence at 24 weeks. With 399 participants per arm and an alpha of .05, the investigators will have 80% power to detect a ≥10% difference in abstinence at 24 weeks. The ASAP Trial will be conducted by a highly experienced team of researchers and enrolling centres, who have previously completed three smoking cessation RCTs, including two in cardiac patients.

Expected Outcomes:

Smoking cessation is essential to reduce morbidity and mortality in this high-risk patient population. ASAP will provide regulators, health care professionals, and smokers with important information about the efficacy of aggressive varenicline and nicotine e-cigarettes therapy for smoking cessation in people at an elevated cardiovascular risk.

03

Conditions studied

  • Acute Coronary Syndrome
  • Cardiovascular Diseases

Keywords

  • acute coronary syndrome
  • smoking cessation
  • randomized controlled trial
  • varenicline
  • e-cigarettes
  • cardiovascular disease
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients currently hospitalized or being discharged from hospital who have suffered an ACS, defined as follows:

    i. MI, defined by positive troponin T, troponin I, or CK-MB levels (as defined by institution-specific cut-offs) and ≥ 1 of the following:

    1. Ischemic symptoms for ≥ 20 min;
    2. (ECG) changes indicative of ischemia (ST-segment elevation or depression);
    3. Development of pathological Q waves on the ECG

    ii. Unstable angina with significant coronary artery disease, defined by all of the following:

    1. Ischemic symptoms for ≥ 20 min;
    2. ECG changes indicative of ischemia (ST-segment changes);
    3. At least one lesion ≥ 50% on angiogram performed during the current hospitalization.

    [Note: patients who undergo cardiac catheterization or percutaneous coronary intervention (PCI) or coronary artery bypass graft (CABG) surgery will be eligible provided they are able to start varenicline in-hospital and nicotine e-cigarette at discharge.]

    OR

    Outpatients with the following diagnoses/conditions:

    i. Cardiovascular:

    1. Coronary artery disease documented with angiography or coronary CT;
    2. Previous ACS, MI, stable or UA;
    3. Previous coronary revascularization (e.g. PCI or CABG). ii. Renovascular:

    a. Chronic kidney disease. iii. Cerebrovascular:

    a. Previous cerebral infarction or transient cerebral ischemic attack. iv. Peripheral vascular:

    1. Abdominal aortic aneurysm > 3.0 cm or previous aortic aneurysm surgery;
    2. Ankle-brachial pressure index of \< 0.9 or intermittent claudication;
    3. Documented carotid artery disease;
    4. Lower-limb amputation;
    5. Previous lower-limb bypass surgery or angioplasty.

    v. ≥1 risk factors:

    1. ≥ 27 kg/m2;
    2. Dyslipidemia;
    3. Family history (first degree relative: parents or siblings only) of coronary heart disease or stroke before the age of 60 years;
    4. Hypertension;
    5. Males aged ≥ 55 years/females aged ≥ 60 years;
    6. Diabetes mellitus. vi. Heart-related conditions:

    <!-- -->

    1. Atrial fibrillation or flutter;
    2. Cardiomyopathy;
    3. Heart failure;
    4. Left ventricular hypertrophy (evidenced by echocardiography or ECG);
    5. Valvular disease (evidenced by echocardiography).
  2. Smoked on average ≥ conventional cigarettes/day for the past year;
  3. Age ≥18 years;
  4. Motivated to quit smoking according to the Motivation To Stop Scale (MTSS) (≥ level 5);
  5. Able to understand and provide in English or French;
  6. If randomized to the combination arm (varenicline and e-cigarette plus counseling), willing and able to purchase e-cigarettes with the following properties: rechargeable, closed system that uses sealed cartridges or pods, tobacco or no flavor only, and nicotine strength of 20 mg/ml (2%) or less;
  7. Likely to be available for 52 weeks of follow-up.

Exclusion criteria

Exclusion Criteria:

  1. Pregnant or lactating females;
  2. Use of any of the following in the 30 days prior to eligibility assessment:

    i. Varenicline or bupropion for smoking cessation; ii. Nicotine or non-nicotine e-cigarettes; iii. Other anti-craving medication (e.g., naltrexone, acamprosate) with the potential to alter substance-seeking behaviors;

  3. Use of nicotine replacement therapy (NRT) in the 7 days prior to eligibility assessment [Note: If participant is prescribed non-study NRT while hospitalized, they can continue using the non-study NRT until being discharged, even while taking the products. Upon discharge, use of the non-study NRT should be stopped.];
  4. Use of varenicline or e-cigarettes (nicotine or non-nicotine) for ≥14 days consecutively in the past year;
  5. Previous serious adverse reaction to varenicline and/or e-cigarettes (nicotine or non-nicotine);
  6. or Killip Class III or IV at the time of randomization;
  7. Any unstable psychiatric disorder (as per enrolling physician);
  8. Renal impairment with creatinine levels ≥2 times or ≤15;
  9. Use of any illegal drugs in the past year;
  10. Planned use of cannabis (smoked) or other tobacco products (smoked or other) during the study period. [Note: use of cannabis which is not smoked is permitted (e.g., edibles, ingested or vaped oils). However, methods which involve combustion could invalidate biochemical validation via exhaled carbon monoxide.]
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
798 participants (estimated)

Study arms

  • Active comparator
    Combination Therapy Arm (Varenicline and Nicotine E-Cigarettes Plus Counseling)

    Patients in the combination therapy arm will be supplied funds and instructions for the purchase of e-cigarettes and cartridges/pods upon hospital discharge and at the week 4 and 12 clinic visits. As with standard NRTs such as the gum, inhaler, and lozenge, the investigators expect smokers will self-regulate administration according to their withdrawal symptoms. Use will be monitored via self-report for telephone follow-ups. At clinic visits, patients will be asked to bring their e-cigarettes, used and unused cartridges/pods, and purchasing receipts. Patients will be advised regarding the signs and symptoms of nicotine toxicity and of an allergic reaction.

    Combination Product: Combination Therapy Arm (Varenicline and Nicotine E-Cigarettes Plus Counseling)

  • Other
    Varenicline Plus Counseling

    All patients will begin varenicline in-hospital upon randomization. For the first 3 days, patients will take a 0.5 mg tablet once a day. They will then take a 0.5 mg tablet twice a day for the following 4 days, and one 1 mg tablet twice a day from day 8 onward for the remainder of the 12-week treatment. Use will be monitored via self-report for telephone follow-ups and return of all unused tablets at the end of the treatment period. Should a patient experience severe side effects (such as headache, nausea, vomiting, dizziness, dyspepsia, fatigue, insomnia, abnormal dreams, constipation, or flatulence) on day 8 onward, the varenicline dose should be reduced from 1 mg twice daily to 0.5 mg twice daily prior to study medication discontinuation.

    Other: Varenicline Plus Counseling

Interventions

  • Combination productCombination Therapy Arm (Varenicline and Nicotine E-Cigarettes Plus Counseling)

    Varenicline and nicotine e-cigarettes plus counseling

  • OtherVarenicline Plus Counseling

    Varenicline plus counseling

06

What researchers measure

Primary outcomes

  1. Number of participants with 7-day point prevalence smoking abstinence

    Biochemically-validated 7-day point prevalence smoking abstinence at 24 weeks, defined as self-reported abstinence in the past 7 days with exhaled carbon monoxide ≤ 10 ppm.

    Time frame: 24 weeks

Secondary outcomes

  1. Number of participants with continuous smoking abstinence

    Biochemically-validated continuous abstinence at 4, 12, and 24 weeks, defined as self-reported abstinence since baseline with exhaled carbon monoxide ≤ 10 ppm at all clinic follow-ups, and self-reported 0 cigarette smoked in the past 7 days at telephone follow-ups (1, 2, 8, and 18 weeks).

    Time frame: 1, 2, 8, and 18 weeks

  2. Number of participants with prolonged smoking abstinence

    Prolonged abstinence, defined as self-reported abstinence at all clinical and telephone follow-ups after an initial 2-week grace period with exhaled carbon monoxide ≤ 10 ppm at 4, 12, and 24 weeks, and self-reported 0 cigarette smoked in the past 7 days at the 8, and 18 weeks telephone follow-ups.

    Time frame: 4, 8, 12, 18, and 24 weeks

  3. Change in daily cigarette consumption

    Change in self-reported daily conventional cigarette consumption from baseline compared to 24 weeks.

    Time frame: 24 weeks

  4. Number of participants with ≥50% reduction in daily cigarette consumption

    Proportion of participants with ≥50% reduction in self-reported daily cigarette consumption from baseline compared to 24-weeks.

    Time frame: 24 weeks

  5. Number of participants with point prevalent abstinence or ≥50% reduction in daily cigarette consumption at 24 weeks

    Composite endpoint of point prevalent abstinence or ≥50% reduction in daily cigarette consumption at 24 weeks

    Time frame: 24 weeks

  6. Frequency of Serious Adverse Events (SAEs)

    The number of serious adverse events (SAE) reported over the 12 week treatment period. A SAE is defined as an adverse event which requires in-patient hospitalization or prolongation of existing hospitalization, that causes congenital malformation, that results in persistent or significant disability or incapacity, that is life-threatening, or that results in death.

    Time frame: 12 weeks

  7. Frequency of Adverse Events (AEs)

    The number of adverse events reported over the 12 week treatment period. An adverse event is any unfavorable and unintended sign, symptom, or disease temporally associated with the use of the trial drug, whether or not considered related to the e-cigarettes or varenicline.

    Time frame: 12 weeks

  8. Frequency of drop-outs

    The number of drop-outs due to side effects of the e-cigarettes or varenicline over the 12 week treatment period.

    Time frame: 12 weeks

  9. Spirometry measurements (subset)

    For a sub-set of 100 patients, 50 from each arm, randomized at 4-5 recruiting sites, undergoing spirometry measurements, differences in FVC, FEV1, and FEV1/FVC ratio as well as measures of small airways disease between pre- and post-bronchodilator at week 24 from baseline.

    Time frame: 24 weeks

  10. O2 Cost Diagram and COPD Assessment Test (subset)

    For the same sub-set of 100 patients undergoing spirometry measurements randomized at 4-5 recruiting sites, the difference in the O2 Cost Diagram and the CAT at week 24 from baseline.

    Time frame: 24 weeks

Other outcomes

  1. Number of patients with 7-day point prevalence smoking abstinence at 4, 12, and 52 weeks

    Biochemically-validated 7-day point prevalence smoking abstinence at 4, 12, and 52 weeks, defined as self-reported abstinence in the past 7 days with exhaled carbon monoxide ≤ 10 ppm.

    Time frame: 4, 12, and 52 weeks

  2. Number of patients with continuous abstinence at 4, 12, 24, and 52 weeks

    Biochemically-validated continuous abstinence at 4, 12, 24, and 52 weeks, defined as self-reported abstinence since baseline with exhaled carbon monoxide ≤ 10 ppm at all follow-up visits.

    Time frame: 4, 12, 24, and 52 weeks

  3. Number of prolonged smoking abstinence at all follow-up visits

    Prolonged abstinence, defined as self-reported abstinence at all follow-up visits after an initial 2 weeks grace period with exhaled carbon monoxide ≤ 10 ppm at 4, 12, 24, and 52 weeks.

    Time frame: 4, 12, 24, and 52 weeks

  4. Change in daily cigarette consumption at all other weeks

    Change in self-reported daily conventional cigarette consumption from baseline at weeks 1, 2, 4, 8, 12, 18, and 52.

    Time frame: 1, 2, 4, 8, 12, 18, and 52 weeks

  5. Number of patients with ≥50% reduction in daily cigarette consumption at all other weeks

    Proportion of participants with ≥50% reduction in self-reported daily cigarette consumption from baseline at weeks 1, 2, 4, 8, 12, 18, and 52.

    Time frame: 1, 2, 4, 8, 12, 18, and 52 weeks

  6. Number of participants with point prevalent abstinence or ≥50% reduction in daily cigarette consumption at all other weeks

    Composite endpoint of point prevalent abstinence or ≥50% reduction daily cigarette consumption at weeks 1, 2, 4, 8, 12, 18, and 52.

    Time frame: 1, 2, 4, 8, 12, 18, and 52 weeks

  7. Spirometry measurements (subset) at all other clinic visits

    For the sub-set of 100 patients undergoing spirometry measurements, differences in FVC, FEV1, and FEV1/FVC ratio as well as measures of small airways disease between pre- and post-bronchodilator at week 4, week 12, and week 52.

    Time frame: 4, 12, and 52 weeks

  8. O2 Cost Diagram and COPD Assessment Test (subset) at all other clinic visits

    For the sub-set of 100 patients undergoing spirometry measurements, the difference in the O2 Cost Diagram and the CAT at weeks 4, 12, and 52 compared to baseline.

    Time frame: 4, 12, and 52 weeks

  9. Number of patients averaging ≥1 pill of varenicline/day

    To describe the proportion of participants averaging ≥1 pill/day for varenicline over the treatment period.

    Time frame: 12 weeks

  10. To describe e-cigarette pattern of use

    To describe the nicotine e-cigarette pattern of use during the treatment period in terms of self-reported average sessions per week, and puffs per session (7-day recall).

    Time frame: 12 weeks

07

Study locations

13 of 13 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2023 (actual). Primary completion is estimated for Mar 2026, 37 months after the start.

Of 39 phase 3 interventional studies under Acute Coronary Syndrome, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 52. This study's planned 37 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 1, 2022
First posted
Feb 25, 2022
StartActual
Feb 2, 2023
Primary completionEst.
Mar 7, 2026
CompletionEst.
Mar 7, 2027
Last update
Apr 29, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 29, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05257629
Lead sponsor
Sir Mortimer B. Davis - Jewish General Hospital
Responsible party
Mark Eisenberg, MD (Principal Investigator, Sir Mortimer B. Davis - Jewish General Hospital) — Principal investigator
First posted
Feb 25, 2022
Start date
Feb 2, 2023
Primary completion
Mar 7, 2026 (estimated)
Completion
Mar 7, 2027 (estimated)
Last update
Apr 29, 2025

Study contacts

Tabitha Finch
Contact
ASAP.Trial@ladydavis.ca
514-340-8222 ext. 23240
Carole Bohbot
Contact
carole.bohbot@ladydavis.ca
514-340-8222 ext. 22790

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion